PONATINIB HYDROCHLORIDE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PONATINIB HYDROCHLORIDE (PONATINIB HYDROCHLORIDE).

How it works

Ponatinib is a potent oral tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant, as well as VEGFR, PDGFR, FGFR, and SRC kinases.

What the body does with it

Metabolism	Metabolized primarily by CYP3A4 and to a lesser extent by CYP2C8, CYP2D6, CYP3A5, and esterases.
Excretion	Primarily hepatobiliary excretion; ~87% of dose recovered in feces (mostly as metabolites), <5% in urine as unchanged drug.
Half-life	Terminal half-life of approximately 29 hours (range 18–48 h) supporting once-daily dosing; steady-state reached within 7 days.
Protein binding	92–99% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent Vd/F approximately 1100–1200 L (not weight-adjusted; if estimated at 70 kg, ~15.7–17.1 L/kg), indicating extensive tissue distribution.
Bioavailability	Absolute oral bioavailability is not determined; relative bioavailability after oral administration is adequate; absorption is unaffected by food, though high-fat meal reduces Cmax by ~21% and delays Tmax by 2 hours.
Onset of Action	Oral: Clinical response (reduction in WBC counts in CML) observed within 1–2 weeks, with maximal cytogenetic response typically after 3–6 months.
Duration of Action	Once-daily dosing maintains continuous target inhibition; duration of molecular response is sustained with continued therapy; median duration of response in clinical trials varies but is typically months to years depending on disease phase.

Classification & Brands

Dosing & administration

45 mg orally once daily with or without food.

Dosage form	TABLET
Renal impairment	No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl <30 mL/min), reduce dose to 30 mg once daily.
Liver impairment	For Child-Pugh A or B, reduce starting dose to 30 mg once daily. For Child-Pugh C, reduce starting dose to 30 mg once daily and monitor closely; further dose reductions may be considered based on tolerability.
Pediatric use	Safety and efficacy not established in pediatric patients; no approved dosing guidelines.
Geriatric use	No specific dose adjustment required based on age alone; monitor renal function and consider age-related decline in CrCl for dose adjustments per renal impairment guidelines.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PONATINIB HYDROCHLORIDE (PONATINIB HYDROCHLORIDE).

Breastfeeding	No data on ponatinib excretion in human milk. M/P ratio unknown. Because of potential serious adverse reactions in breastfed infants (e.g., myelosuppression, thrombosis), discontinue breastfeeding or discontinue drug.
Teratogenic Risk	Ponatinib is embryotoxic and fetotoxic in animal studies at exposures below human therapeutic levels. First trimester: No adequate human data; avoid use unless benefit > risk. Second/third trimester: Potential for fetal harm based on animal findings; use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

WARNING: ARTERIAL THROMBOTIC EVENTS, HEPATOTOXICITY, AND HEART FAILURE. Ponatinib has been associated with life-threatening arterial thrombosis, including myocardial infarction and stroke. Also associated with severe hepatotoxicity and heart failure. Use only in patients with resistance or intolerance to prior TKI therapy.

Side Effect Profile

Serious Effects

Absolute Contraindications

["None reported"]

Clinical Precautions

Precautions

["Arterial thrombotic events (including MI, stroke)","Venous thromboembolic events","Heart failure","Hepatotoxicity","Pancreatitis","Hemorrhage","Hypertension","Fluid retention","Wound healing complications","Tumor lysis syndrome"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

PONATINIB HYDROCHLORIDE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PONATINIB HYDROCHLORIDE (PONATINIB HYDROCHLORIDE).

How it works

Ponatinib is a potent oral tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant, as well as VEGFR, PDGFR, FGFR, and SRC kinases.

What the body does with it

Metabolism	Metabolized primarily by CYP3A4 and to a lesser extent by CYP2C8, CYP2D6, CYP3A5, and esterases.
Excretion	Primarily hepatobiliary excretion; ~87% of dose recovered in feces (mostly as metabolites), <5% in urine as unchanged drug.
Half-life	Terminal half-life of approximately 29 hours (range 18–48 h) supporting once-daily dosing; steady-state reached within 7 days.
Protein binding	92–99% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent Vd/F approximately 1100–1200 L (not weight-adjusted; if estimated at 70 kg, ~15.7–17.1 L/kg), indicating extensive tissue distribution.
Bioavailability	Absolute oral bioavailability is not determined; relative bioavailability after oral administration is adequate; absorption is unaffected by food, though high-fat meal reduces Cmax by ~21% and delays Tmax by 2 hours.
Onset of Action	Oral: Clinical response (reduction in WBC counts in CML) observed within 1–2 weeks, with maximal cytogenetic response typically after 3–6 months.
Duration of Action	Once-daily dosing maintains continuous target inhibition; duration of molecular response is sustained with continued therapy; median duration of response in clinical trials varies but is typically months to years depending on disease phase.

Classification & Brands

Dosing & administration

45 mg orally once daily with or without food.

Dosage form	TABLET
Renal impairment	No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl <30 mL/min), reduce dose to 30 mg once daily.
Liver impairment	For Child-Pugh A or B, reduce starting dose to 30 mg once daily. For Child-Pugh C, reduce starting dose to 30 mg once daily and monitor closely; further dose reductions may be considered based on tolerability.
Pediatric use	Safety and efficacy not established in pediatric patients; no approved dosing guidelines.
Geriatric use	No specific dose adjustment required based on age alone; monitor renal function and consider age-related decline in CrCl for dose adjustments per renal impairment guidelines.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PONATINIB HYDROCHLORIDE (PONATINIB HYDROCHLORIDE).

Breastfeeding	No data on ponatinib excretion in human milk. M/P ratio unknown. Because of potential serious adverse reactions in breastfed infants (e.g., myelosuppression, thrombosis), discontinue breastfeeding or discontinue drug.
Teratogenic Risk	Ponatinib is embryotoxic and fetotoxic in animal studies at exposures below human therapeutic levels. First trimester: No adequate human data; avoid use unless benefit > risk. Second/third trimester: Potential for fetal harm based on animal findings; use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["None reported"]

Clinical Precautions

Precautions

Clinical Tips & Counseling

Drug interactions

Loading safety data…